Key Takeaways
- When it comes to the industry-wide patent cliff coming in the back half of the decade, a lucky few are well positioned to weather the storm.
- A Scrip analysis of Evaluate Pharma data shows the drug makers that are positioned lose 15% or less of 2025 forecast US revenues from drugs going off patent from 2026-2030.
- Novo Nordisk, Sanofi, Gilead, Eli Lilly and Bayer are five of the top drug manufacturers well positioned from an LOE perspective.
The biopharmaceutical industry is heading into a tumultuous period from 2026-2030, which will be marked by the loss of exclusivity (LOE) in the US of some of the industry’s biggest-selling brands
When it comes to the industry-wide patent cliff coming in the back half of the decade, a lucky few are even
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
